Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antibiotics and Immunotherapy: Too Much of Anything is Bad!
Gopalakrishnan V, Sellman BR, Cohen TS, Dennis PA. Gopalakrishnan V, et al. Eur Urol. 2020 Oct;78(4):544-545. doi: 10.1016/j.eururo.2020.07.027. Epub 2020 Aug 15. Eur Urol. 2020. PMID: 32811714 No abstract available.
Dysregulation of COVID-19 related gene expression in the COPD lung.
Watson A, Öberg L, Angermann B, Spalluto CM, Hühn M, Burke H, Cellura D, Freeman A, Muthas D, Etal D, Belfield G, Karlsson F, Nordström K, Ostridge K, Staples KJ, Wilkinson T; MICA II Studygroup. Watson A, et al. Respir Res. 2021 May 29;22(1):164. doi: 10.1186/s12931-021-01755-3. Respir Res. 2021. PMID: 34051791 Free PMC article.
StarGazer: A Hybrid Intelligence Platform for Drug Target Prioritization and Digital Drug Repositioning Using Streamlit.
Lee C, Lin J, Prokop A, Gopalakrishnan V, Hanna RN, Papa E, Freeman A, Patel S, Yu W, Huhn M, Sheikh AS, Tan K, Sellman BR, Cohen T, Mangion J, Khan FM, Gusev Y, Shameer K. Lee C, et al. Among authors: gopalakrishnan v. Front Genet. 2022 May 31;13:868015. doi: 10.3389/fgene.2022.868015. eCollection 2022. Front Genet. 2022. PMID: 35711912 Free PMC article.
Intervention strategies for microbial therapeutics in cancer immunotherapy.
Gopalakrishnan V, Weiner B, Ford CB, Sellman BR, Hammond SA, Freeman DJ, Dennis P, Soria JC, Wortman JR, Henn MR. Gopalakrishnan V, et al. Immunooncol Technol. 2020 May 20;6:9-17. doi: 10.1016/j.iotech.2020.05.001. eCollection 2020 Jun. Immunooncol Technol. 2020. PMID: 35757236 Free PMC article. Review.
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.
Cascone T, Kar G, Spicer JD, García-Campelo R, Weder W, Daniel DB, Spigel DR, Hussein M, Mazieres J, Oliveira J, Yau EH, Spira AI, Anagnostou V, Mager R, Hamid O, Cheng LY, Zheng Y, Blando J, Tan TH, Surace M, Rodriguez-Canales J, Gopalakrishnan V, Sellman BR, Grenga I, Soo-Hoo Y, Kumar R, McGrath L, Forde PM. Cascone T, et al. Among authors: gopalakrishnan v. Cancer Discov. 2023 Nov 1;13(11):2394-2411. doi: 10.1158/2159-8290.CD-23-0436. Cancer Discov. 2023. PMID: 37707791 Free PMC article. Clinical Trial.
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N. Sade-Feldman M, et al. Among authors: gopalakrishnan v. Cell. 2018 Nov 1;175(4):998-1013.e20. doi: 10.1016/j.cell.2018.10.038. Cell. 2018. PMID: 30388456 Free PMC article.
Working with Human Tissues for Translational Cancer Research.
Reuben A, Gopalakrishnan V, Wagner HE, Spencer CN, Austin-Breneman J, Jiang H, Cooper ZA, Wargo JA. Reuben A, et al. Among authors: gopalakrishnan v. J Vis Exp. 2015 Nov 26;(105):53189. doi: 10.3791/53189. J Vis Exp. 2015. PMID: 26649748 Free PMC article.
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.
Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Cooper ZA, et al. Among authors: gopalakrishnan v. Oncoimmunology. 2016 Feb 2;5(3):e1136044. doi: 10.1080/2162402X.2015.1136044. eCollection 2016 Mar. Oncoimmunology. 2016. PMID: 27141370 Free PMC article.
393 results